8-K: 10x Genomics Q1 2026 Results: Atera Launch Boosts Outlook

10x Genomics reported Q1 2026 results with a 3% revenue decrease year-over-year, but excluding one-time items, revenue grew 9%, driven by new product launches and strategic partnerships.

Summary

• 10x Genomics reported Q1 2026 revenue of $150.8 million, a 3% decrease compared to Q1 2025.
• Excluding $16.8 million in one-time license and royalty revenue from Q1 2025, revenue increased by 9% year-over-year.
• The company launched Atera, a new platform for spatial whole-transcriptome analysis, expected to ship in the second half of 2026.
• A partnership with Bioptimus was announced to create foundational datasets connecting biology with disease outcomes using the Xenium platform, expanding to Atera later.
• Gross margin improved to 70% from 68% in the prior year period, attributed to lower warranty costs and inventory write-downs.
• Operating expenses decreased by 15% to $123.2 million, primarily due to lower legal and personnel costs.
• Operating loss narrowed to $17.0 million from $39.3 million in Q1 2025, and net loss decreased to $13.5 million from $34.4 million.
• Cash, cash equivalents, and marketable securities stood at $539.8 million as of March 31, 2026, an increase of $112.9 million from the prior year.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive report, with adjusted revenue growth and expense management being positive, but the overall revenue decline and continued net loss temper enthusiasm.

Positives

• Revenue increased by 9% year-over-year when excluding one-time license and royalty revenue from Q1 2025.
• Gross margin improved to 70% in Q1 2026 from 68% in Q1 2025.
• Operating expenses decreased by 15% to $123.2 million.
• Operating loss significantly narrowed to $17.0 million from $39.3 million in the prior year.
• Net loss decreased to $13.5 million from $34.4 million in the prior year.
• Cash, cash equivalents, and marketable securities increased by $112.9 million year-over-year to $539.8 million.
• Double-digit growth in Single Cell consumables reaction volumes.
• Double-digit growth in Spatial consumables revenue.

Negatives

• Total revenue decreased by 3% to $150.8 million in Q1 2026 compared to Q1 2025.
• The company reported an operating loss of $17.0 million and a net loss of $13.5 million.

Risks

• The company's financial and operating results could be materially affected by risks and uncertainties discussed in its most recently filed 10-K and subsequent SEC filings.
• The launch of Atera is expected to begin shipping in the second half of 2026, with potential delays impacting revenue recognition.

Future Outlook

The company is maintaining its full-year 2026 revenue guidance of $600 million to $625 million. Excluding non-recurring license and royalty revenue from 2025, this represents 0% to 4% growth over full-year 2025.

Management Comments

• "We had a solid start to the year, with double-digit growth in Single Cell consumables reaction volumes and double-digit growth in Spatial consumables revenue."
• "The biggest highlight is our recent launch of Atera, which represents the most significant product introduction in our history."
• "We are extremely encouraged by the extraordinary early customer response."

Industry Context

StockSavvy.ai notes that 10x Genomics' focus on single cell and spatial biology, coupled with the launch of the Atera platform and a partnership with Bioptimus for AI-driven data initiatives, aligns with the broader industry trend towards more sophisticated and scalable biological analysis tools, particularly in the context of drug discovery and disease research.

Legal Proceedings

• A patent litigation settlement in Q1 2025 resulted in $16.8 million of one-time license and royalty revenue.

Stakeholder Impact

• Shareholders: Continued net losses and a slight year-over-year revenue decrease may be a concern, but adjusted growth and improved margins offer some positive signals. The launch of Atera and strategic partnerships could drive future value.
• Employees: Reduced operating expenses, including personnel costs, could indicate cost-saving measures, but the company's growth trajectory remains key.
• Customers: The launch of the Atera platform and the STELA initiative with Bioptimus suggest continued innovation and potential for enhanced biological insights.
• Creditors: The company's strong cash position of $539.8 million provides a buffer for ongoing operations and investments.

Next Steps

• Begin shipping the Atera platform in the second half of 2026.
• Expand the STELA initiative with Bioptimus to include the Atera platform over time.
• Continue to monitor and manage operating expenses.
• Achieve full-year 2026 revenue guidance of $600 million to $625 million.

Key Dates

Recommendation

The company shows signs of operational improvement with reduced losses and better margins, and the launch of Atera is a significant positive. However, the reported revenue decline and maintained, modest full-year guidance suggest a period of stabilization rather than strong growth, warranting a 'hold' recommendation until the impact of new products and partnerships becomes clearer.

Keywords

10x Genomics, Single Cell Biology, Spatial Biology, Atera Platform, Q1 2026 Results, Financial Report, Life Science Technology, Biotechnology